TrialEuropean journal of haematology2025

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Aurore Perrot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.